Antisense compounds directed against human CSF-1

Details for Australian Patent Application No. 2003216778 (hide)

Owner TRANSGENE INSTITUT CURIE

Inventors Balloul, Jean-Marc; Scholl, Suzy; Lacoste, Jerome

Agent Freehills

Pub. Number AU-A-2003216778

PCT Number PCT/FR03/00007

PCT Pub. Number WO2003/059395

Priority 02/00029 03.01.02 FR

Filing date 3 January 2003

Wipo publication date 30 July 2003

International Classifications

A61K 048/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

Event Publications

31 July 2003 Complete Application Filed

  Priority application(s): 02/00029 03.01.02 FR

4 September 2003 Application Open to Public Inspection

  Published as AU-A-2003216778

31 July 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003216779-METHOD FOR CONTROLLING COMMUNICATION CHANNELS AND BASE STATION AND TERMINAL THEREFOR

2003216777-Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octan e, the preparation thereof and the application of same in therapeutics